SUNGKYUNKWAN UNIVERSITY
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1398-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.skku.edu
Clinical Trials
13
Active:0
Completed:6
Trial Phases
1 Phases
Not Applicable:8
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Not Applicable
8 (100.0%)Proprioceptive Error Correction for Post-Stroke Upper Limb Rehabilitation
Not Applicable
Recruiting
- Conditions
- Ischemic StrokeProprioception
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 3
- Registration Number
- NCT07156955
- Locations
- 🇰🇷
Shinchon Severance Rehabilitation Hospital, Seoul, Seoul, South Korea
Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy
Completed
- Conditions
- Pregnancy RelatedBenzodiazepines Causing Adverse Effects in Therapeutic UseCongenital Anomaly
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 3094227
- Registration Number
- NCT04856436
- Locations
- 🇰🇷
Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of
Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy
- Conditions
- Pregnancy RelatedInfluenza Virus Vaccine Adverse Reaction
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 300000
- Registration Number
- NCT04579822
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
- Conditions
- Pneumococcal Vaccine Adverse Reaction
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 1000000
- Registration Number
- NCT04551248
- Locations
- 🇰🇷
Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab
- Conditions
- InfectionRheumatoid Arthritis
- Interventions
- Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 9508
- Registration Number
- NCT04115423
- Locations
- 🇰🇷
Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of
- Prev
- 1
- 2
- Next
News
Researchers Develop 3D-Printing 'Glue Gun' for Real-Time Bone Graft Surgery
South Korean researchers have developed a modified glue gun that can 3D-print bone grafts directly onto fractures during surgery, eliminating the need for pre-made implants.